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ABSTRACT
Alternative splicing (AS) is a fundamental mecha-
nism for the regulation of gene expression. It affects
more than 90% of human genes but its role in the
regulation of pancreatic beta cells, the producers of
insulin, remains unknown. Our recently published
data indicated that the ‘neuron-specific’ Nova1 splic-
ing factor is expressed in pancreatic beta cells. We
have presently coupled specific knockdown (KD) of
Nova1 with RNA-sequencing to determine all splice
variants and downstream pathways regulated by this
protein in beta cells. Nova1 KD altered the splicing of
nearly 5000 transcripts. Pathway analysis indicated
that these genes are involved in exocytosis, apop-
tosis, insulin receptor signaling, splicing and tran-
scription. In line with these findings, Nova1 silenc-
ing inhibited insulin secretion and induced apoptosis
basally and after cytokine treatment in rodent and hu-
man beta cells. These observations identify a novel
layer of regulation of beta cell function, namely AS
controlled by key splicing regulators such as Nova1.
INTRODUCTION
Alternative splicing (AS) affects more than 90% of human
genes (1). It allows individual genes to produce structurally
and functionally distinct mRNAs and their relative protein
isoforms, explaining the discrepancy between the estimated
24,000 protein-coding genes in the human genome and the
>100,000 different proteins synthesized (2). Changes in AS
may have a major impact on cell survival, exposure of novel
antigenic epitopes, alteration of surface location of antigens
and post-translational modifications (3–5). There is a grow-
ing interest in the role of AS in several autoimmune diseases
(6,7), but nearly nothing is known on its role in pancreatic
beta cell function and its dysfunction and apoptosis in dia-
betes.
We have recently shown that beta cell exposure to pro-
inflammatory cytokines modifies AS of more than 3000 ex-
pressed genes, including genes involved in chemotaxis and
apoptosis, and of more than 50 splicing-regulating proteins
(8,9). Our group has recently clarified the cross-talk between
the diabetes candidate gene Glis3, cytokines and the splic-
ing factor SRp55. This splicing factor is down-regulated af-
ter cytokine treatment or knockdown (KD) of the diabetes
candidate gene Glis3 providing an important ‘proof of con-
cept’ for the role of AS in diabetes (9).
Regulation of splicing involves the cooperation be-
tween serine/arginine-rich (SR) proteins, heterogeneous nu-
clear ribonucleoproteins (hnRNP) and several other tissue-
specific regulators (10). Nova1 has been defined as a
‘neuron-specific’ splicing factor (11–13) but we recently re-
ported that Nova1 is also expressed in the beta cells of the
human and rat islets of Langerhans (8).
Nova1 binds to YCAY-rich elements (14–17) and
it is a central regulator of neuronal AS (16,18–24).
By combining protein–RNA crosslinking and Nova-
immunoprecipitation, Darnell and colleagues identified
>200 Nova RNA targets in the mouse brain (13). These
transcripts regulate the development of brain synapses (19).
Some of the known Nova1 target genes in brain are also
expressed in beta cells, including Gabrg2, Neuroligin and
Neurexin family members, Inhibitory synapse-associated
neuroligin and neurexin binding partners (8) but the global
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role of Nova1 in pancreatic beta cell function and survival
remains unknown.
High-throughput mRNA sequencing (RNA-seq) pro-
vides the opportunity to study AS in an unbiased manner
and on a genome-wide scale. RNA-seq allows the discovery
of novel transcripts and the estimation of their abundance.
This is extremely useful when dealing with poorly anno-
tated transcriptomes (25) and is a powerful method to iden-
tify splicing networks regulated by different splicing factors
(26).
In this study, we have combined siRNA technology,
RNA-seq and functional studies to characterize the role of
Nova1 in the regulation of beta cell mRNA splicing and its
implication in the function and viability of these cells. This
combined approach showed that Nova1 is a master regula-
tor of AS in beta cells, controlling key pathways involved in
beta cell function and survival. These findings unveil a novel
role for Nova1, outside the brain, and indicate that AS is a
novel layer of regulation of pancreatic beta cell dysfunction
and apoptosis in diabetes.
MATERIALS AND METHODS
Ethic statements
Human islet collection and handling were approved by the
local Ethical Committee in Pisa, Italy.Wistar rats were used
according to the rules of the BelgianRegulations forAnimal
Care with approval of the Ethical Committee for Animal
Experiments of the ULB, Brussels, Belgium.
Culture of INS-1E cells, INS-1 832/13 cells, FACS-purified
rat beta cells and human islet cells
Rat insulin-producing INS-1E cells, kindly provided by C.
Wollheim, University of Geneva, Geneva, Switzerland (27),
were cultured in RPMI 1640 medium supplemented with
5% FBS, 10 mM HEPES, 1 mM Na-pyruvate and 50 M
2-mercaptoethanol (28). INS-1 832/13 cells were cultured
in the same medium as INS-1E cells.
Pancreatic islets were isolated from adultmaleWistar rats
(Charles River Laboratories, Brussels, Belgium) and pri-
mary beta cells FACS-purified (FACSAria; BD Bioscience,
San Jose, CA, USA) and cultured as described (29).
Human islets from four non diabetic donors were iso-
lated in Pisa using collagenase digestion and density gra-
dient purification (30). The donors (two women, two men)
were 51±14 years old and had a BMI 22±1 [kg/m2]. Beta
cell content, as evaluated by immunofluorescence for insulin
using a specific anti-insulin antibody (8), was 62±6%.
The human islets were cultured in M199 culture medium
containing 5.5 mM glucose and sent to Brussels, Belgium,
within 1–5 days after isolation, where they were dispersed
and cultured in Ham’s F-10 medium containing 6.1 mM
glucose (Invitrogen-Life Technologies, Paysley, UK) as de-
scribed (8,31).
Cell treatment
The following cytokine concentrations were used, based
on previous dose-response experiments performed by our
group (32–34): recombinant human IL-1 (R&D Systems,
Abingdon, UK) 10 or 50 units/ml respectively for INS-1E
cells or primary rat beta cells and human islet cells; recom-
binant rat IFN- (R&D Systems) 100 or 500 units/ml re-
spectively for INS-1E cells and primary rat beta cells, and
human IFN- (Peprotech, London, UK) 1000 units/ml for
human islet cells.
RNA interference
The siRNAs used in the study are described in Supplemen-
tary Table S1. The optimal conditions and concentrations
of siRNA for beta cell transfection (30 nM) were previously
established by our group (31,35). Cells were transfected us-
ing the Lipofectamine RNAiMAX lipid reagent (Invitrogen)
as previously described (35,36). Allstars Negative Control
siRNA (Qiagen, Venlo, The Netherlands) was used as neg-
ative control (siCTL). This siCTL does not affect beta cell
gene expression or insulin release, as compared with non-
transfected cells (35). After 16 h of transfection, cells were
cultured for a 24 h or 48 h recovery period before exposure
to cytokines.
Assessment of cell viability
The percentage of viable, apoptotic and necrotic cells was
determined after 15-min incubation with DNA-binding
dyes propidium iodide (5 g/ml; Sigma-Aldrich, Poole,
UK) and Hoechst dye 33342 (5 g/ml; Sigma-Aldrich) by
two independent researchers, one of them unaware of sam-
ples identity. A minimum of 600 cells were counted for
each experimental condition. In some experiments, apop-
tosis was also confirmed by caspase-3 and -9 cleavage and
KD of Bim, a key pro-apoptotic BH3-only protein in beta
cells (37).
RNA-sequencing
Three preparations of FACS-purified rat primary beta cells
were used for RNA-sequencing as described (8). Briefly, to-
tal RNA was isolated using the RNeasy Micro Kit (Qia-
gen) which favors purification of RNA molecules longer
than 200 nucleotides, and sample preparation was done as
described by the manufacturer (Illumina, Eindhoven, The
Netherlands). mRNA was purified from 1 g total RNA
using oligo (dT) beads, before it was fragmented and ran-
domly primed for reverse transcription followed by second-
strand synthesis to create ds cDNA fragments. The gen-
erated cDNA had undergone paired-end repair to convert
overhangs into blunt ends. After 39-monoadenylation and
adaptor ligation, cDNAs were purified on a 2% agarose gel
and 200 basepair (bp) products were excised from the gel.
Following gel digestion, purified cDNA was amplified by
PCR using primers specific for the ligated adaptors. The
generated libraries were submitted to quality control with
the Agilent bio-analyzer 2100 (Agilent Technologies, Wok-
ingham, UK) before sequencing. The RNA integrity num-
ber values for all samples were 7.5 and above. One micro-
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liter cDNA was loaded on an Agilent DNA chip (DNA-
1000) to verify cDNA quality and quantity. Only libraries
reaching satisfactory conditions were used for sequencing,
on an Illumina HiSeq 2000 system. The raw data generated
during the sequencing procedure on the HiSeq 2000 will be
deposited in Gene Expression Omnibus under submission
number GSE59633.
RNA-seq data analysis
Sequencing reads were mapped to the rat genome (version
Rnor 5.0) using Tophat software version 2.02 (25) and the
default options. Mapped reads were used with Cufflinks
software suite in combination with rat transcripts anno-
tations from Ensembl database (38) version 70 for tran-
scripts assembly using the novel transcripts discovery op-
tions. Transcript quantification from the mapped reads and
the newly assembled transcripts was performed using the
Flux Capacitor approach developed by one of us (M.S.)
(http://flux. sammeth.net, (39)). All genes and transcripts
have been assigned a relative coverage rate as measured
in RPKM units (‘reads per kilobase per million mapped
reads’) (40). Lists of differentially expressed genes and tran-
scripts were generated from the Flux Capacitor output us-
ing custom scripts in Perl or R.
To define genes up- or down-regulated byNova1KD, the
log2 of the proportion between the sum of the RPKM for all
gene transcripts under Nova1 KD condition and the same
sum in control condition was taken as measure of change
in gene expression. The P-value was obtained by perform-
ing a Fisher exact test (number of reads mapped to the gene
and number of reads mapped to all other genes in theNova1
KD condition versus the control condition) and corrected
by the Benjamini–Hochberg method (taking for each gene
the three samples as independent tests). A difference in gene
expression was considered significant if the corrected P-
value was lower than 0.05. As an additional criteria, a gene
with corrected P < 0.05 was considered to be ‘modified by
Nova1KD’ only if its expression changed significantly in the
same direction––i.e. ‘up’ or ‘down’––across all of the three
samples. In order to quantify Nova1KD-modified splicing,
differences in ‘splice indices’––the proportion between the
RPKM for a transcript and the sum of the RPKM for all
the transcripts from the same gene––under Nova1KD con-
dition were compared to the control condition. Addition-
ally, a P-value on the significance of changes in splicing pat-
terns was obtained by performing a Fisher exact test (num-
ber of reads assigned to a certain transcript after deconvo-
lution versus the number of reads mapped to all other tran-
scripts of the same gene, comparingNova1KDwith control
condition) and was corrected by the Benjamini–Hochberg
method (taking for each transcript the three samples as in-
dependent tests). A change in ASwas considered significant
after applying the same criteria as for the gene expression.
Up/down-regulated genes/transcripts were analyzed using
Ingenuity Pathway Analysis (IPA, Ingenuity Systems, http:
//www.ingenuity.com) or UCSC TFBS DAVID (Database
for Annotation, Visualization and Integrated Discovery,
http://david.abcc.ncifcrf.gov) (41). Potential binding sites
for Nova1 were identified using the SpliceAid database
(http://www.introni.it/splicing.html).
Large-scale prediction of Nova1 binding site clusters in mod-
ified exons
To predict potential YCAY Nova1 binding sites, 200 nu-
cleotides were extracted on both sides of each intron-
exon junctions of all regulated exons as in previous stud-
ies (20,42). To avoid overlapping sequences, the short ex-
ons were shared equally on both junctions. For negative
control, 10 sets of an equal number of sequences were ex-
tracted following the same procedure for exons selected
randomly from expressed but not regulated by Nova1. We
then used the Regulatory Sequences Analysis Tools soft-
ware suite (43) program matrix-scan (44) to predict clus-
ters of YCAY motif in the regulated exons and negative
control. The matrix-scan program reports individual motif
as well as regions where they occur in clusters, called cis-
regulatory elements enriched regions (CRER). These are
regions that have a higher number of predicted site occur-
rences than expected by chance. To detect them, first in-
dividual sites were predicted using the Nova1 motif. They
were filtered using a threshold on aP-value of 2.5e-03.Win-
dows of variable sizes from 10 to 60 nucleotides were then
defined over the input sequences and the number of pre-
dicted sites was counted within each window. Second, the
expected number of matches was calculated within each
window and then used to estimate the significance of the
over-representation of matches. The binomial distribution
was used to estimate the probability to observe by chance at
least as many matches as those counted in the window. This
cluster probability, called ‘CRER P-value’, has to be distin-
guished from the ‘site P-value’: the site P-value estimates
the risk of false positive for an individual match, whereas
the CRER P-value estimates the risk of error when consid-
ering that a window contains more matches than expected
by chance. A Wilcoxon–Mann–Whitney test was used to
compare theP-values of predictedYCAYclusters inNova1-
modified exons and in negative control.
Human islet and rat beta cell RNA extraction, RT-PCR and
qRT-PCR
Independent human islet preparations, clonal INS-1E and
FACS-purified primary rat beta cells were used for val-
idation and mechanistic experiments. PolyA mRNA was
isolated using the Dynabeads mRNA DIRECT kit (In-
vitrogen) and reverse transcribed as previously described
(28). qRT-PCR was done using the iQ SYBR Green Su-
permix (BIO-RAD, Nazareth Eke, Belgium) on a Light-
Cycler (Roche Diagnostics, Mannheim, Germany) or iCy-
cler MyiQ Single Color (BIO-RAD) instrument (45,46).
Data were expressed as the number of copies using the
standard curve method and corrected for the housekeep-
ing genes -actin or glyceraldehyde-3-phosphate dehydro-
genase (GAPDH). Splice variants were examined by con-
ventional PCR. Primers used for qRT- and RT-PCR are
listed in Supplementary Table S2.
Glucose oxidation and insulin secretion
D-[U-14C] glucose (specific activity: 300 mCi/mM, concen-
tration: 1 mCi/ml, Perkin Elmer, Waltham,MA, USA) was
used to evaluate glucose oxidation in control and Nova1
Nucleic Acids Research, 2014, Vol. 42, No. 18 11821
KD cells exposed to different glucose concentrations as de-
scribed (47). The rate of glucose oxidation was expressed as
pmol/120 min·105 cells.
For determination of insulin secretion, INS-1E cells
were incubated for 1 h in glucose-free RPMI GlutaMAX-
I medium and then incubated for 30 min in Krebs-Ringer
solution. Cells were then exposed to 1.7 mM, 16.7 mM or
16.7 mM glucose with forskolin (20M) for 30 min. Insulin
was measured in the supernatant by the rat insulin ELISA
kit (Mercodia, Uppsala, Sweden). Results were normalized
by the insulin content measured after cell lyses.
Electrophysiological measurements
Experiments were conducted on single INS-1 832/13 cells
after transfection as described above. The siRNA used
in these experiments is listed in the Supplementary Ta-
ble S2 as siNova1#2. Whole-cell currents were measured
as described previously (48) using an EPC-10 patch-
clamp amplifier and the software Pulse (Heka Elektronik,
Lamprecht/Pfalz, Germany; version 8–31). A current-
voltage (I–V) protocol was performed on each cell to mea-
sure the inward voltage-dependent current. In this protocol
a 50-ms depolarization from −70 mV to increasing volt-
ages from −50 mV to +40 mV was applied to the cell.
The standard extracellular solution consisted of (in mM):
118 NaCl, 20 tetraethyl-ammonium chloride (TEA-Cl; to
block voltage-gated K+ currents), 5.6 KCl, 2.6 CaCl2, 1.2
MgCl2, 5 glucose and 5 HEPES (pH 7.4 using NaOH). The
pipette solutions contained 125 Cs-Glut, 10 NaCl, 10 CsCl,
1 MgCl2, 0.05 EGTA, 3Mg-ATP, 5 HEPES (pH 7.15 using
CsOH) and 0.1 cAMP.
Western blot
After cell culture and treatment, cells were washedwith cold
phosphate buffered saline and lysed using Laemmli buffer.
Total protein was extracted and resolved by 6–12% sodium
dodecyl sulphate-polyacrylamide gel electrophoresis, trans-
ferred to a nitrocellulose membrane and immunoblotted
with the specific antibodies for the protein of interest as
described (31). The primary antibodies were goat anti-
Nova1 (0.03 g/ml; Abcam, Cambridge, UK), rabbit anti-
cleaved caspases 9 and 3 (1:1000; Cell Signaling, Danvers,
USA), rabbit anti-PLC1 (1:1000; Santa Cruz Biotech-
nology, CA, USA), rabbit anti-Bim (1:1000; Cell Signal-
ing), rabbit anti-FoxO3A (1:1000; Cell Signaling), rab-
bit anti-Phospho-FoxO3A (1:1000; Cell Signaling), rab-
bit anti-Akt (1:1000; Cell Signaling) and mouse anti--
tubulin (1:10000, Sigma). The proteins were detected us-
ing horseradish peroxidase-conjugated secondary antibody
(1:5000; Santa Cruz Biotechnology). Protein signal was vi-
sualized using chemiluminescence Supersignal (Pierce) and
quantified using Scion Image (Scion Corporation, Fred-
erick, MD, USA). The intensity values for the proteins
were corrected by the values of the housekeeping protein
-tubulin.
Statistical analysis
The statistical analysis of the RNA-seq data is described
above. Data for the confirmation and functional studies are
Figure 1. Nova1 regulates the AS of several genes in pancreatic beta cells.
(A) Primary rat beta cells were transfected with siCTL or siNova1 and then
collected after 48 h for mRNA expression analyses. Expression of Nova1
after its KD is shown. Results are mean ± SEM (n = 7). ***P < 0.001
versus siCTL by paired t-test. (B) Representative western blot of Nova1
expression after its KD in INS-1E cells (n = 5). (C) Agarose gel showing
thatNova1 controls AS ofGabrg2 exon 9, its own exon 4 andNeurexin1 site
4. Long and short indicates the variants with or without the corresponding
analysed exons. The results shown are representative of five different exper-
iments where Nova1 has been KD. The percentage of inclusion/exclusion
of each exonwas quantified by densitometry (considering the highest value
in each individual experiment as 1) and is shown under the respective gels.
*P < 0.05 or **P < 0.01 versus siCTL by paired t-test.
shown as means ± SEM. Comparisons were performed by
paired two-tailed Student’s t-test or by ANOVA followed by
a paired Student’s t-test with Bonferroni’s correction as ad-
equate. A P ≤ 0.05 was considered statistically significant.
RESULTS
Nova1 acts as a splicing factor in pancreatic beta cells
In order to elucidate the function of Nova1 in pancre-
atic beta cells, we used RNA interference to KD Nova1 in
FACS-purified primary rat beta cells obtaining a decrease
of Nova1 expression of >50% (Figure 1A). This siRNA-
induced decrease of Nova1 expression was also confirmed
at protein level in INS-1E cells (Figure 1B). Nova1 was pre-
viously shown to modulate the splicing of Neurexin1 (20),
to cause exon 9 inclusion in Gabrg2 transcripts (21) and to
produce its own exon 4 exclusion inmouse brain (22). Nova1
KD in INS-1E cells induced similar changes in these three
genes, causing an increase in exon 9 exclusion in Gabrg2
transcripts, a decrease in its own exon 4 exclusion and a
change in the splicing pattern of Neurexin1 (Figure 1C).
These results were reproduced in primary beta cells (data
not shown), confirming that modulation of Nova1 expres-
sion indeed affects AS in beta cells.
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RNA-sequencing of pancreatic beta cells followingNova1KD
In order to understand the global role of Nova1 in the reg-
ulation of gene expression and AS in beta cells, three inde-
pendent preparations of FACS-purified rat beta cells (purity
between 90 and 95%) were exposed to siControl (siCTL) or
siNova1, and then RNA-sequenced. We obtained an aver-
age of 177 million total reads (paired end 100 nucleotides)
reaching a high transcriptome resolution, which enabled
quantification of transcript abundance and analysis of AS.
The reads were aligned onto the rat genome (Rnor 5.0), al-
lowing the mapping of 77–85% of the raw reads (Supple-
mentary Table S3).
We next used the Cufflinks software suite (25) to iden-
tify potentially novel transcripts (Supplementary Figure
S1A). The number of transcripts detected as present with a
RPKM higher than 0 was 43,460, corresponding to 18,257
known genes. Compared to the 29,094 transcripts (26,313
genes) annotated in Ensembl version 70, this represents a
significant increase in the knowledge of the beta cell rat
transcriptome, with 2.4 isoforms per gene in the present
newly assembled transcriptome as compared to the 1.1 iso-
forms per gene annotated in Ensembl (Supplementary Fig-
ure S1B andC).Most of these genes and transcripts are well
expressed (RPKM>0.5) in beta cells as shown in Supple-
mentary Figure S1D and E.
Of the 18,257 genes detected as present by the RNA-
seq, 3373 (18%) were significantly modified by a 48-h KD
of Nova1, with 2374 and 999 respectively up- and down-
regulated. Only 8% of these modified genes, however, had a
fold change higher than 1.5-fold (Figure 2A). On the other
hand, the changes induced by the Nova1 KD were more
marked at the isoform level, with 57% of the isoforms mod-
ified showing a fold change >1.5 (Figure 2B). This suggests
that Nova1 affects both transcription and splicing in beta
cells, but with a more marked effect on splicing (see below).
Nova1 KD modified the splicing of 4961 (11% of the to-
tal) isoforms, with 2702 and 2259 isoforms respectively up-
and down-regulated. Similarly to the fold-change distribu-
tion, the distribution of the splicing index showed that 53%
of spliced isoforms had a splicing index––the difference be-
tween the proportion between the RPKM of a transcript
and the sum of the RPKM for all the transcripts from the
same gene––higher or lower than the threshold percentage
of 10% (Figure 2C). This further supports the role of Nova1
as a splicing factor in pancreatic beta cells. Analyzes of the
number of exons included or excluded in Nova1-silenced
pancreatic beta cells indicated respectively 2202 and 1818
exons preferentially included or excluded after Nova1 KD.
It has been shown that Nova1 modifies 325 exons corre-
sponding to 267 genes in mouse brain (20), of which 189
(71%) are also expressed in pancreatic beta cells. Nova1
modulates the splicing of 80% of the common genes shared
by brain and pancreatic beta cells (present data, hypergeo-
metric P-value: 3.9E-26).
It has been shown that Nova1 binds to the YCAY motif
in brain that appears in clusters in the vicinity of intron-
exon junctions (20,42). We set out to predict potential
YCAY clusters in all Nova1-modified exons to check if
they showed a particular enrichment. As reported previ-
ously, Nova1-regulated splicing is position dependent: al-
Figure 2. Effect of Nova1 KD on the fold change of genes and isoforms.
(A–B) The histograms show the distributions of fold change at the gene
level (A) and at the isoform level (B) afterNova1KD and RNA-seq analy-
sis of three independent primary rat beta cell preparations. Only 8% of all
the modified genes show a log fold change higher than 1.5 (up-regulated)
or lower than 0.67 (down-regulated). At the isoform level this proportion
is much higher, i.e. 57%. (C) Distribution of the ‘splicing index’ values (see
Results for details about the splicing index) after Nova1 KD. Most of the
significantly alternatively spliced isoforms have a splicing index higher than
10% (delimited by the two vertical lines). (D) Overview of the key Nova1
modified pathways and transcripts after IPA pathways analysis.
ternative exons are more often included when Nova1 binds
to downstream introns and more often excluded via bind-
ing to upstream introns (20,42). We thus predicted sepa-
rately YCAY clusters in the regions surrounding the up-
stream and downstream exon-intron junction regions for
up-regulated and down-regulated exons after Nova1 KD,
respectively. The results showed more significant YCAY
clusters in the downstream regions of down-regulated ex-
ons after Nova1 KD compared to randomly selected ex-
ons (Wilcoxon–Mann–Whitney P-value: 0.002). The cor-
responding upstream regions of the same exons showed
less significant YCAY clusters (Wilcoxon–Mann–Whitney
P-value: 0.027; Supplementary Figure S1F). These obser-
vations are in line with the regulatory code of Nova1 as
it promotes exon inclusion when bound to upstream re-
gions. Nova1 KD promotes the down-regulation in those
exons. In contrast, the downstream junction regions of up-
regulated exons after Nova1 KD showed less significant
YCAY clusters (Wilcoxon–Mann–Whitney P-value: 0.036;
Supplementary Figure S1F).We did not observe differences
in the occurrence of significant YCAY clusters in the up-
stream regions (Supplementary Figure S1G).
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We next analyzed the nature of the primary rat beta
cell transcript networks modified by Nova1 (the complete
list is accessible at http://lmedex.ulb.ac.be/data.php with a
password provided upon request) using IPA (Figure 2D
and Supplementary Figure S2A) and the DAVID software
(Figure 2D). This analysis suggested that the main path-
ways affected by Nova1 are exocytosis, calcium signaling,
apoptosis, insulin receptor signaling, splicing and transcrip-
tion; there were also several kinases and phosphatases regu-
lated by Nova1 (Figure 2D). IPA showed that differentially
spliced transcripts belong prominently to the functions
‘Cell-to-Cell Signaling interaction’, ‘Cell Death’, ‘Molecu-
lar Transport’, ‘Post-Translational Modification’ and ‘Cel-
lular Assembly and Organization’ (Supplementary Figure
S2A). We also performed IPA analysis on the 154 common
transcripts modified by Nova1 in brain and beta cells, ob-
serving that they belong to similar categories to those de-
scribed for the complete list of target genes in beta cells
(Supplementary Figure S2B). Moreover, detailed analysis
of the canonical pathways of Nova1 target genes shared by
brain and beta cells indicates that they are mainly involved
in calcium signaling and synaptic long-term potentiation.
In order to further validate our RNA-seq analysis, we se-
lected additional Nova1-target genes for independent eval-
uation by RT-PCR and confirmed their changes in splic-
ing after Nova1KD in INS-1E cells (Supplementary Figure
S3). The selected genes play a role in key cellular functions
such as splicing (Sfrs9), potassium channels (Kcnma1), ki-
nases (Mapk9 andMap3k9), Rho GTPases (Arhgef12) and
reductases (Cyb5r4).
Inhibition of Nova1 impairs insulin release and decreases
voltage-dependent Ca2+ current
Nova1 KD decreased glucose or glucose + forskolin-
induced insulin release, but did not affect basal insulin re-
lease (Figure 3A). In order to determine if the observed de-
crease in insulin secretion inNova1KD cells was mostly re-
lated to defective exocytosis, as suggested by the observa-
tions above, or to a putative decrease in glucose metabolism
and ATP generation, we measured glucose metabolism in
INS-1E cells KD forNova1. There was no difference in glu-
cose oxidation between the control and Nova1 KD cells,
respectively (1.7 mM glucose, 1.08 ± 0.21 versus 1.07 ±
0.22 and 16.7 mM glucose, 6.12 ± 0.74 versus 7.23 ± 0.78
pmol/105 cells·120−1 min).
Since Nova1 modifies the splicing of several calcium
channels (Figure 2D), which may also modulate insulin
exocytosis (49), we next examined the voltage-dependent
Ca2+ current after Nova1 KD in INS-1 832/13 cells. Sim-
ilar to the observations made in INS-1E cells (Figure 3A),
Nova1 KD also inhibits insulin secretion in INS-1 832/13
cells (data not shown). In parallel, Nova1 KD induced a
35±10% decrease (n = 28–33; P < 0.05) in the voltage-
dependent Ca2+ current. This was confirmed by measure-
ments of the current-voltage relationship using 50-ms de-
polarizations from −70 mV to voltages between −50 and
+40 mV. The measured current consists of a rapidly acti-
vating Na+ current and a slower activating Ca2+ current.
Maximum current was achieved when the membrane was
depolarized to 0 mV (Figure 3B and C). These results are in
agreement with the observed reduced insulin secretion (Fig-
ure 3A).
In line with the pathway analysis suggesting that Nova1
modulates genes involved in exocytosis, we found in the
RNA-seq data two target genes of Nova1 that are involved
in insulin secretion, namely PLCβ1 and SNAP-25. A de-
crease in the expression of the main isoform of the phos-
pholipase PLCβ1 in MIN6 cells decreases insulin secretion
(50). We presently observed that splicing of PLCβ1 is mod-
ified after Nova1 KD, with a main decrease of the isoform
b (Figure 3D) that correlates with the observed decrease
in insulin secretion. We identified potential binding sites
for Nova1 in the sequence of PLCβ1 using the SpliceAid
database. The expression ofPLCβ1 variants was alsomodi-
fied (40±4% decrease, P< 0.001) after Nova1 KD confirm-
ing that Nova1 affects transcription. Nova1 modified the
splicing of the vesicle fusion protein Snap25 (51) switching
exon 5a/5b and leading to a lower expression of exon 5b
in INS-1E cells (Figure 3E). Isoform b is more effective in
mediating Ca 2+-triggered secretion (52) and the change in
splicing is functionally significant, as previously described
in the brain (53). We confirmed that Snap25 has potential
Nova1 binding sites in the sequences of the different exons
5a, 5b and in the surrounding introns, with a high score
according to SpliceAid database (Figure 4A). We designed
a specific siRNA that targets splice variant b but not the
a one (Figure 4B). KD of the splice variant b in INS-1E
cells decreased glucose or glucose + forskolin-induced in-
sulin release (Figure 4C), similar to the findings observed
after Nova1 KD.
Nova1 regulates insulin receptor AS in pancreatic beta cells
Analyzing the genes of the upstream pathway of the FoxO
family of transcription factors (54,55), we observed an in-
teresting finding revealed by the RNA-seq data, namely
that Nova1 KD modifies the splicing of the insulin recep-
tor (INSR) gene. Due to AS of exon 11, the INSR exists in
two isoforms, A and B, which differ by the absence or pres-
ence of a 12 amino acid sequence respectively (Figure 5A).
There is evidence for lower signaling potential for INSR-A
as compared to INSR-B (54,56). The number of RNA-seq
reads that cover the exon 11 was clearly decreased follow-
ing Nova1 silencing (Figure 5B), and using the SpliceAid
database we identified 10 potential binding sites for Nova1
with high score in INSR exon 11 and the intron 11 (Fig-
ure 5C). We confirmed the change in splicing by RT-PCR
(Figure 5D), observing a decrease of 30±4% (n = 3; P <
0.05) of the exon 11 inclusion afterNova1KD (Figure 5D).
This resulted in an increase in the isoform INSR-A and a
decrease in the isoform INSR-B.Additional studies are now
required to clarify the functional impact of this change.
Nova1 KD increases basal and cytokine-induced apoptosis
The expression of Nova1 was significantly decreased when
rat beta cells were exposed to the pro-inflammatory cy-
tokines IL-1 + IFN- (Figure 6A). These cytokines in-
duce beta cell death via the intrinsic pathway of apoptosis
(37,57), and we next examined whether inhibition of Nova1
by specific siRNAs also led to beta cell apoptosis.
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Figure 3. Nova1 regulates insulin secretion and voltage-dependent current influx. INS-1E cells (A, D, E) and INS-1 832/13 cells (B–C) were transfected
with siCTL or siNova1. After 48 h cells were used for insulin secretion assay (A), voltage-dependent current influx analysis (B–C) protein analysis (D) and
mRNA analysis (E). (A) INS-1E cells were incubated for 30 min with 1.7 mM glucose, 16.7 mM glucose or 16.7 mM glucose plus forskolin (20 M) (n =
5) and the insulin released evaluated by ELISA. *P< 0.05 versus siCTL by paired t-test. (B) A current voltage protocol where 50-ms depolarizations from
−70 mV to voltages between −50 mV and +40 mV were applied to INS-1 832/13 cells. Shown in the figure are the currents measured when a siCTL cell
(gray trace) and a siNova1 cell (black trace), respectively, were depolarized to 0 mV. (C) The average sustained current Isus (measured as described in B),
charge (Q) and peak-current Ip as a function of the membrane voltage (V) are from the experiments described in B. Ip is a measure of the voltage-dependent
Na+ current and Isus and Q are measures of the voltage-dependent Ca2+ current. Data are representative of n = 28 to 33 experiments in each group. (D)
Schematic overview of PLC1 indicating the splicing variants and a representative western blot (n = 4) of PLC1 variants expression after Nova1 KD.
-tubulin was used as a control for protein loading. The quantification of PLC1 expression is shown. ***P < 0.001 versus siCTL by paired t-test. (E)
Snap25 AS was evaluated by RT-PCR after Nova1 KD. The quantification of both splice variants by qRT-PCR is shown. **P < 0.01 versus siCTL by
paired t-test. An agarose gel of one experiment is shown. (D) and (E) are representative of four similar experiments.
Nova1 KD (Supplementary Figure S4) increased basal
and cytokine-induced apoptosis in INS-1E cells, FACS-
purified rat primary beta cells and dispersed human islets
(Figure 6B, C and D, respectively), suggesting a key role of
Nova1 for maintenance of beta cell viability. Apoptosis sec-
ondary to Nova1 KD, with or without concomitant expo-
sure to pro-inflammatory cytokines, wasmediated by the in-
trinsic (mitochondrial) pathway of apoptosis, as suggested
by increased cleavage of caspases 9 and 3 in INS-1E cells
(Figure 6E and F).
Beta cell survival is critically dependent on the bal-
ance between anti- and pro-apoptotic Bcl-2 proteins (37).
The BH3-only protein Bim is an important mediator of
cytokine-induced beta cell apoptosis (58) andNova1KD in-
duced Bim protein expression (Figure 7A and B). Bim has
three main isoforms generated by AS, namely BimEL, BimL
and BimS (59), andNova1KD induced a similar increase in
these three isoforms (the blots are quantified in Figure 7B).
To confirm the role of Bim in Nova1 KD-induced apop-
tosis, we performed a double KD of Nova1 and Bim. We
have previously shown that this Bim siRNA markedly de-
creases the expression of the three splice variants of Bim
in cytokine-treated INS-1E cells (58), which was presently
confirmed, with a Bim depletion >50% (data not shown).
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Figure 4. KD of Nova1-regulated Snap25 splice variant b decreases in-
sulin secretion. (A) Snap25 exons 5a and 5b (bold) and the surrounding
intron sequences are shown. Potential binding sites for Nova1 are high-
lighted in gray. (B) Schematic overview of Snap25 alternative exons 5a and
5b. The line indicates the position of the siRNA designed to KD Snap25
splice variant b. INS-1E cells were transfected with control or a Snap25
splice variant b siRNA and after 48 h collected for mRNA analysis. A rep-
resentative agarose gel (of five similar experiments) showing the expression
of both variants and gapdh is shown. (C) INS-1E cells were incubated for
30 min with 1.7 mM glucose, 16.7 mM glucose or 16.7 mM glucose plus
forskolin (20 M) (n= 5) and the insulin released evaluated by ELISA. *P
< 0.05 versus siCTL by paired t-test.
Silencing of Bim abrogated the basal and cytokine-induced
increase in apoptosis byNova1KD (Figure 7C), supporting
a role for Bim in the observed increase in beta cell apoptosis
following Nova1 KD.
Nova1 silencing modifies the expression of the transcription
factors FoxO1 and FoxO3A
The RNA-seq analysis indicated that Nova1 KD modifies
the expression of members of the FoxO family of transcrip-
tion factors, whose activity is regulated by the insulin recep-
tor signaling pathway (54,55). The RNA-seq data showed
an up-regulation of the expression of FoxO1 after Nova1
KD. This result was confirmed by qRT-PCR in INS-1E
cells (Supplementary Figure S5A). Of interest, there was
also an increase in the expression of FoxO3A after Nova1
KD. FoxO3A is a transcription factor directly involved in
Bim transcription (60) and we confirmed by western blot
the up-regulation of total-FoxO3A (Figure 7D and Supple-
mentary Figure S5B), paralleled by a decrease in expression
of the phosphorylated formafterNova1KD(Figure 7Dand
Supplementary Figure S5C). FoxO family of transcription
factors are downstream targets of the serine/threonine pro-
tein kinase B (PKB)/Akt (61). We observed a decrease in
Figure 5. Nova1 modifies the splicing of the insulin receptor exon 11 in
beta cells. (A) Schematic figure representing INSR splice variants. Arrows
indicate the primers used for the analysis of exon 11. (B) Representative
scheme of the RNA-seq reads covering INSR exon 11 in control andNova1
KD preparations. (C) Sequences of INSR exon 11 and intron 11. Potential
binding sites identified for Nova1 are highlighted in gray. (D) INS-1E cells
were transfectedwith siCTLor siNova1 and collected after 48 h formRNA
analysis. INSR exon 11 splicing was evaluated by RT-PCR. The agarose
gel is representative of three independent experiments. The percentage of
inclusion/exclusion of exon 11 is shown in the graph. *P < 0.05 versus
siCTL by paired t-test.
the expression of Akt after Nova1 KD which may affect
FoxO3A phosphorylation (Figure 7E and Supplementary
Figure S5D). Double KD of FoxO3A and Nova1 resulted
in a decrease in Bim protein expression (Figure 7F) and cell
death (Figure 7G), suggesting that Nova1 regulates Bim ex-
pression and cell death at least in part via modulation of
FoxO3A.
DISCUSSION
We have presently coupled KD of the splicing factor Nova1
with deep sequencing of the rat transcriptome to deter-
mine the nature of the transcripts modulated by Nova1 in
FACS-purified pancreatic beta cells. Nova1 was previously
described as a ‘neuron-specific’ splicing factor (12,14,19),
but we presently show that it has also a major role in pan-
creatic beta cell AS, function and viability.
Nova1 is expressed in human islets at levels comparable
to brain; this expression is>10-fold higher than in other tis-
sues (8). The present transcriptome data suggest that Nova1
is indeed a master regulator of splicing in pancreatic beta
cells, modifying the splicing of nearly 5000 transcripts. Of
interest, 80% of the genes previously identified as Nova1-
regulated in mouse brain (20) and expressed in pancreatic
beta cells are also modulated by this splicing factor in rat
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Figure 6. Nova1 KD increases apoptosis under basal condition and fol-
lowing cytokine treatment. Primary rat beta cells were exposed to the pro-
inflammatory cytokines IL-1 + IFN- for 48 h and then collected for
mRNA expression analyses. Results are mean ± SEM (n = 8). **P < 0.01
versus untreated by paired t-test (A). After transfection with siRNA con-
trol or siRNA Nova1 (> 50% inhibition of Nova1 expression in the three
cell types) INS-1E cells (B, E, F), FACS-purified primary rat beta cells
(C) and dispersed human islets (D) were exposed or not to cytokines (n
= 4). After 24 h for INS-1E cells or 48 h for primary beta cells or dis-
persed human islets, apoptosis was evaluated. (E) Cleaved caspases-9 and
-3 expression afterNova1KD. Blots are representative of four independent
experiments. -tubulin was used as a control for protein loading. (F) Den-
sitometry analysis of western blot for cleaved caspases 9 and 3 normalized
by the housekeeping protein -tubulin. Results are mean ± SEM (n = 4).
*P < 0.05, **P < 0.01 or ***P < 0.001 versus siCTL untreated or after
cytokine treatment by paired t-test.
beta cells. Nova1 binds to the YCAY motif in brain. This
motif appears in clusters in the vicinity of intron-exon junc-
tions (20,42) and we have observed more significant YCAY
clusters in the downstream regions of down-regulated exons
compared to randomly selected exons.
We have confirmed in independent experiments that
Nova1 regulates AS of Gabrg2 and Snap25 in pancreatic
beta cells. AS of these two mRNAs is regulated byNova1 in
the brain (20). These findings are in agreement with previ-
ous observations indicating that beta cells share expression
of a large number of genes and proteins with the central ner-
vous system (45,62,63).
Pathway analysis revealed that Nova1 target genes are
implicated in crucial beta cell functions such as exocyto-
sis, transcription, insulin receptor signaling, splicing and
apoptosis andwe confirmed in independent experiments the
changes in splicing of 10 genes involved in these functions
following Nova1 KD. The fact that splicing is one of the
Figure 7. Bim mediates the potentiation of apoptosis in Nova1-deficient
cells. INS-1E cells were transfected with control or Nova1 siRNAs. After
48 h, cells were collected for western blot analysis. (A) One representative
western blot of Bim variants expression is shown. (B) Densitometry analy-
sis of the western blots for Bim splicing variants. Results are mean ± SEM
(n= 5). *P< 0.05 or **P< 0.01 versus siCTL by paired t-test. (C) INS-1E
cells transfected with control, Nova1 and Bim siRNAs were exposed to cy-
tokines for 24 h; apoptosis was then measured using nuclear dyes. Results
are mean ± SEM (n = 5). ***P < 0.001 versus siCTL without cytokines;
@@@P < 0.001 versus siNova1, ###P < 0.001 versus siBim; +++P < 0.001
versus siNova1 + siBim; $$$P < 0.001 as indicated by the bars. ANOVA
followed by paired t-test with Bonferroni’s correction. (D) Western blot of
total-FoxO3A and P-FoxO3A after Nova1 KD. -tubulin was used as a
control for protein loading. Blots are representative of five experiments.
(E) Western blot of Akt after Nova1 KD is shown. -tubulin was used as a
control for protein loading. The blot is representative of four experiments.
(F) Western blot showing Bim expression after Nova1 KD, FoxO3A KD
(with two different siRNAs F#1 and F#2) and the double KD of Nova1
and FoxO3A (n = 3). (G) Apoptosis was measured using nuclear dyes af-
ter Nova1 KD, FoxO3A KD and the double KD of Nova1 and FoxO3A.
Results are mean ± SEM (n = 4). ***P < 0.001 versus siCTL and $$P <
0.01 as indicated by the bars. ANOVA followed by paired t-test with Bon-
ferroni’s correction.
key pathways identified as Nova1-regulated is in line with
the above-described impact of Nova1 in AS and serves as
an internal validation of the present approach.
We initially confirmed that the observed modulation of
exocytosis by Nova1 KD is accompanied by a decrease in
insulin secretion and the voltage-dependent Ca2+ current,
while there is no change in glucose metabolism. Two genes
potentially involved in the regulation of insulin secretion,
namely PLCβ1 (50) and Snap25 (48,51,64) were identified
by the RNA-seq analysis and in independent confirmation
experiments using RT-PCR, as target genes of Nova1 in
pancreatic beta cells (present data). In order to demonstrate
a direct contribution of Nova1-regulated splicing events
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in a key pancreatic beta cell function, we performed KD
of the Snap25 splice variant b, the variant decreased after
Nova1 KD (Figure 3E) and the most effective one in medi-
ating Ca2+-triggered secretion (52). This decreased glucose-
induced insulin release is similar to the decreased release ob-
served after Nova1KD. The level of decrease observed after
Snap25 splice variant b KD, however, it is not as marked as
when Nova1 is KD probably due to the fact that Snap25
is not the only exocytosis-related gene modified following
Nova1 KD.
Progressive pancreatic beta cell apoptosis induced by pro-
inflammatory cytokines and invading immune cells is a cen-
tral phenomenon in the development of type 1 diabetes (57).
Interestingly, the cytokines IL-1 + IFN- inhibitedNova1
expression in rat beta cells, and Nova1 silencing by specific
siRNAs, alone or in combination with cytokines, resulted
in apoptosis in INS-1E cells, primary rat beta cells and dis-
persed human islets, indicating an important role for Nova1
in the maintenance of beta cell viability. In line with these
observations, Nova1 null mice die postnatally from amotor
deficit associated with apoptotic death of spinal and brain-
stem neurons (23). Apoptosis secondary to Nova1 KD in
beta cells is mediated by the intrinsic (mitochondrial) path-
way of apoptosis via up-regulation of the BH3-only pro-
tein Bim (present data). Bim has been previously shown to
play a central role in cytokine (58)-, virus (65)- and high
glucose (66,67)-induced beta cell death. Bim transcription
is regulated by the transcription factor FoxO3A in breast
cancer cell lines (60), and FoxO3A phosphorylation inhibits
its transcriptional activity (61). We presently observed that
KD of Nova1 up-regulates the expression of FoxO3A and
decreases its phosphorylation, potentially leading to an ac-
crued activation of this transcription factor. FoxO fam-
ily of transcription factors are downstream targets of the
serine/threonine protein kinase B (PKB)/Akt (61). We ob-
served a decrease in the expression of Akt after Nova1 KD
which may mediate the impact of Nova1 on the observed
FoxO3A phosphorylation. The parallel KD of Nova1 and
FoxO3A prevents both up-regulation of Bim and beta cell
apoptosis, indicating that FoxO3A is a key downstream tar-
get of Nova1.
An intriguing finding of the present study is that Nova1
regulates the splicing of the insulin receptor, favoring the ex-
pression of the INSR-A isoform followingNova1 silencing.
We have identifiedNova1 potential binding sites in the exon
11 and the intron 11 of INSR. It has been described that
the splicing factor Mbnl1 promotes insulin receptor exon
11 inclusion (68) and that potential binding sites for Nova1
are present in the intron 11 (68). Inclusion of INSR exon
11 is both developmentally and hormonally regulated and
it is altered in type 2 diabetes, myotonic dystrophy, aging
and cancer (69–72). Neonatal hepatocytes expressing only
INSR-B have increased cell death via the extrinsic pathway
of apoptosis, as suggested by caspases-8 and -3 activation,
while the mitochondrial or intrinsic branch of apoptosis is
activated in neonatal hepatocytes expressing INSR-A (73).
These observations suggest that dysregulation of INSR AS
secondary to Nova1 KD may be one of the factors con-
tributing to beta cell apoptosis.
The fact that Nova1 regulates the splicing and expres-
sion of several transcription factors may explain why the
KD of Nova1 modifies such a large number of transcripts
in pancreatic beta cells. These transcript changes may thus
be at least in part a secondary effect of Nova1 KD, inde-
pendent of the presence of the Nova1 binding motif YCAY
in the modified genes. There are increasing studies support-
ing functional links between transcription and pre-mRNA
splicing (74). Splicing factors can promote transcriptional
elongation directly, as demonstrated for the splicing fac-
tor SC35 (75), while the presence of an intron or a splice
site immediately downstream of a promoter enhances tran-
scription (76), suggesting that factors controlling intron re-
moval are important for physiological transcription. More-
over, U1 snRNA (a member of the spliceosome) associates
with the general transcription factor TFIIH, thus regulat-
ing transcription by pol II besides its role in splicing (77).
The present data indicate that Nova1 has a major role
in beta cell function, controlling the splicing and expres-
sion of key genes involved in transcription, insulin release
and apoptosis. These findings identify a novel layer of reg-
ulation of beta cell function, namely AS controlled by key
splicing regulators such as Nova1. Modifications in AS can
directly cause disease, modify its severity and/or confer
susceptibility to pathogenic stimuli (6,72,78–80). Further-
more, inflammation-modified AS may increase antigenicity
by favoring expression of novel antigenic epitopes, modu-
lating surface location or altering post-translational modi-
fications, as shown in other autoimmune diseases (4,5). The
regulation and role of AS in pancreatic beta cells is ‘terra
incognita’. The present data provides the first chart of this
new territory.
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